Orexin-A

Overview

Orexin-A (also called Hypocretin-1) is a 33-amino acid neuropeptide produced by a small, discrete cluster of neurons in the lateral and perifornical hypothalamus. Despite the small number of neurons that produce it — estimated at roughly 70,000 in the human brain — orexin-A exerts profound influence over wakefulness, arousal, motivation, and energy balance. Its projections extend broadly throughout the central nervous system, touching nearly every brain region involved in sleep-wake regulation, reward processing, and autonomic control.

Orexin-A was independently discovered by two research groups in 1998. Takeshi Sakurai's group at the University of Texas Southwestern identified it while searching for endogenous ligands for orphan G-protein coupled receptors, naming the peptides "orexins" for their apparent appetite-stimulating effects. Simultaneously, Luis de Lecea's group at the Scripps Research Institute discovered the same peptides using subtractive cDNA cloning from the hypothalamus, naming them "hypocretins" for their hypothalamic origin and sequence similarity to the secretin family. Both names remain in use, though "orexin" has become dominant in pharmacological contexts.

The field was transformed when Emmanuel Mignot's laboratory at Stanford demonstrated in 2000 that canine narcolepsy was caused by mutations in the orexin receptor 2 gene, and Masashi Yanagisawa's group showed that orexin knockout mice exhibited narcolepsy-like symptoms. Subsequent human studies confirmed that type 1 narcolepsy with cataplexy results from the autoimmune destruction of orexin-producing neurons, establishing orexin-A as one of the clearest examples of a neuropeptide with a defined disease-causing deficiency.

Amino Acid Sequence

Orexin-A is a 33-amino acid peptide derived from the 131-residue precursor protein prepro-orexin (encoded by the HCRT gene):

QPLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH₂

• Molecular formula: C₁₅₂H₂₄₃N₄₃O₄₄S₄
• Molecular weight: ~3,562 g/mol
• CAS Number: 205640-90-0

Structural features:

• Two intramolecular disulfide bonds — Cys6-Cys12 and Cys7-Cys14, forming a compact N-terminal topology
• C-terminal amidation — required for full biological activity
• Pyroglutamic acid at the N-terminus — protects against aminopeptidase degradation
• These stabilizing modifications give orexin-A a significantly longer half-life and greater lipophilicity than the closely related orexin-B (a 28-residue linear peptide that shares only the C-terminal 28% sequence identity)

Mechanism of Action

Orexin Receptor Subtypes

Orexin-A activates two G-protein coupled receptors with distinct pharmacological profiles:

OX1R (Orexin Receptor 1)

• Orexin-A binds with high affinity (Ki ~20 nM)
• Orexin-B binds with 10-100x lower affinity
• Couples primarily to Gq, activating phospholipase C and calcium signaling
• Highly expressed in the locus coeruleus (norepinephrine), ventral tegmental area (dopamine), and prefrontal cortex

OX2R (Orexin Receptor 2)

• Orexin-A and orexin-B bind with roughly equal affinity (Ki ~40 nM)
• Couples to both Gq and Gi/Go pathways
• Highly expressed in the tuberomammillary nucleus (histamine), dorsal raphe (serotonin), and basal forebrain (acetylcholine)
• OX2R is considered the more critical receptor for maintaining wakefulness, as selective OX2R loss in animal models produces narcolepsy-like phenotypes

Wake-Promoting Circuitry

Orexin neurons serve as a master switch that stabilizes the flip-flop switch between sleep and wakefulness. Their projections activate multiple ascending arousal systems simultaneously:

• Locus coeruleus — norepinephrine release promoting alertness
• Tuberomammillary nucleus — histamine release promoting cortical activation
• Dorsal raphe — serotonin release modulating mood and arousal
• Basal forebrain — acetylcholine release promoting cortical desynchronization
• Ventral tegmental area — dopamine release driving motivation and reward

By simultaneously engaging all these systems, orexin-A prevents inappropriate transitions into sleep during active waking. Loss of this stabilizing input (as in narcolepsy) causes the system to oscillate unpredictably between wake and sleep states.

Metabolic and Appetite Regulation

Despite its name (derived from the Greek "orexis" meaning appetite), the role of orexin-A in feeding is secondary to its wakefulness function. Orexin-A does stimulate food intake when administered centrally, and orexin neurons are responsive to peripheral metabolic signals including glucose, leptin, and ghrelin. However, the appetite effects are now understood primarily as a component of arousal-linked foraging behavior rather than direct hunger signaling.

Research Summary

Pharmacokinetics

• Half-life: Approximately 28 minutes in CSF; shorter in plasma due to peptidase degradation
• BBB penetration: Crosses the blood-brain barrier via simple diffusion — unusual for a peptide of this size, attributed to its two disulfide bonds and lipophilic character
• Metabolism: Degraded by endopeptidases; the disulfide bonds and pyroglutamic acid provide moderate resistance
• Route (research): Intracerebroventricular (ICV), intranasal, intravenous
• Intranasal delivery: Demonstrated to reach the CNS in animal and some human studies; active investigation as a therapeutic route for narcolepsy

Pharmacological Tools

Orexin Receptor Antagonists

The orexin system is currently the primary target of approved sleep medications:

• Suvorexant (Belsomra) — FDA-approved dual orexin receptor antagonist (DORA) for insomnia
• Lemborexant (Dayvigo) — second-generation DORA with refined receptor kinetics
• Vorninostat (Quviviq) — DORA approved in Europe

Orexin Agonists (Investigational)

• TAK-861/danavorexton — oral non-peptide OX2R-selective agonist in Phase 2 trials for narcolepsy
• TAK-994 — oral OX2R agonist; clinical development suspended due to safety signals but provided proof-of-concept that orexin agonism reverses narcolepsy symptoms

Common Discussion Topics

1. Narcolepsy treatment paradigm — Current treatments (stimulants, sodium oxybate) manage symptoms rather than replacing the missing orexin signal. Oral orexin agonists like danavorexton represent the first potential disease-mechanism-targeted therapy.

2. Cognitive enhancement interest — Orexin-A's role in promoting sustained wakefulness and attention has generated interest in cognitive enhancement contexts, though no approved orexin agonist peptide exists.

3. Addiction research — The orexin system's involvement in reward-seeking behavior has made OX1R a target for addiction research, with antagonists showing promise in reducing drug-seeking in preclinical models.

4. Intranasal administration — The ability of orexin-A to cross the BBB and its demonstrated intranasal bioavailability make it one of the few peptides where intranasal delivery has meaningful research support.

5. Metabolic integration — Orexin neurons sit at a crossroads of metabolic and arousal signaling, which explains why sleep disorders frequently co-occur with metabolic dysfunction and why fasting states increase orexin neuron activity.

Related Compounds

• Neuropeptide Y — hypothalamic peptide involved in appetite and energy balance that interacts with orexin circuits
• Ghrelin — appetite-stimulating hormone that activates orexin neurons
• Leptin — satiety hormone that inhibits orexin neurons
• DSIP — delta-sleep-inducing peptide with opposing sleep-promoting properties
• Substance P — neuropeptide involved in pain and arousal signaling